Martha J. Carreño-Gonzalez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martha J. Carreño-Gonzalez has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Gp Grunewald
Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
3 shared publications - A. Katharina Ceranski
Hopp Children’s Cancer Center (KiTZ)
2 shared publications - Clémence Henon
Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
2 shared publications - Florencia Cidre-Aranaz
Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
2 shared publications - Kimberley M. Hanssen
Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
2 shared publications - Shunya Ohmura
Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
2 shared publications
Latest Publications
- Open Access
Oncogenic fusions induce an extensive cancer-restricted cryptic proteome in Ewing sarcoma
How tumors generate a cryptic “dark” proteome absent from healthy tissues, and whether it can be reversibly activated, remains unclear. In Ewing sarcoma, all tumors are driven by EWSR1::ETS fusions, making it a tractable model to study dark proteome activation. Integrating matched transcriptomes, translatomes and proteomes from 48 patient tumors with long-read RNA sequencing, single-cell Ribo-seq, proteomics and immunopeptidomics in cell line models, we show that EWSR1::FLI1 acts as a reversible switch recurrently inducing hundreds of cancer-specific neoproteins. Many arise from canonical coding regions via intragenic transcription start sites, generating truncated or out-of-frame neoproteins. We uncover a fusion-dependent increase in ribosomal readthrough into poly(A) tails, generating a stable 80-amino-acid TRPM4 neoprotein that, despite lacking a stop codon, is the most abundant tumor-specific microprotein across patients. Proteomic, immunopeptidomic, and immunofluorescence analyses validate neoproteins as tumor-restricted antigens, revealing a therapeutically actionable cancer dark proteome controlled by one oncogenic fusion. Highlights: Fusion proteins activate in- and out-of-frame neoproteins through intragenic transcription. Neoproteins exhibit distinct protein structures and localizations compared to their host genes. Mass spectrometry detects 911 cryptic proteins, including 29 EwS neoproteins, 15 HLA-I presented. TRPM4-dORF is a stop-less 80-aa neoprotein with abundant peptide evidence exclusively in EwS.
Open AccessOncogenic fusions induce an extensive cancer-restricted cryptic proteome in Ewing sarcoma
How tumors generate a cryptic “dark” proteome absent from healthy tissues, and whether it can be reversibly activated, remains unclear. In Ewing sarcoma, all tumors are driven by EWSR1::ETS fusions, making it a tractable model to study dark proteome activation. Integrating matched transcriptomes, translatomes and proteomes from 48 patient tumors with long-read RNA sequencing, single-cell Ribo-seq, proteomics and immunopeptidomics in cell line models, we show that EWSR1::FLI1 acts as a reversible switch recurrently inducing hundreds of cancer-specific neoproteins. Many arise from canonical coding regions via intragenic transcription start sites, generating truncated or out-of-frame neoproteins. We uncover a fusion-dependent increase in ribosomal readthrough into poly(A) tails, generating a stable 80-amino-acid TRPM4 neoprotein that, despite lacking a stop codon, is the most abundant tumor-specific microprotein across patients. Proteomic, immunopeptidomic, and immunofluorescence analyses validate neoproteins as tumor-restricted antigens, revealing a therapeutically actionable cancer dark proteome controlled by one oncogenic fusion. Highlights: Fusion proteins activate in- and out-of-frame neoproteins through intragenic transcription. Neoproteins exhibit distinct protein structures and localizations compared to their host genes. Mass spectrometry detects 911 cryptic proteins, including 29 EwS neoproteins, 15 HLA-I presented. TRPM4-dORF is a stop-less 80-aa neoprotein with abundant peptide evidence exclusively in EwS.
- Open Access
Dynamic oncogene activity metabolically reprograms the tryptophan– kynurenine–AHR axis driving immune evasion and tumor progression in Ewing sarcoma
How activational changes of driver oncogenes can promote metabolic reprogramming and cancer progression is largely uncharted territory. To address this issue, we employed Ewing sarcoma (EwS) as a model as it is driven by a single driver oncogene, namely chimeric EWSR1::ETS fusion transcription factors, whose fluctuating expression levels promote diverse transcriptional programs. While EWSR1::ETS-high cells display a rather sessile but proliferative phenotype and EWSR1::ETS-low cells are more invasive, the mechanisms underlying these different phenotypes remain poorly characterized. Here, using an integrative functional genomics approach, we show that low EWSR1::ETS fusion activity in patient tumors associates with poor outcome and increased signaling of the aryl hydrocarbon receptor (AHR). AHR signaling enrichment correlates with increased tumor infiltration by immunosuppressive cells and worse overall patient survival. Knockdown of EWSR1::ETS in EwS spheroid models cultured in human plasma-like media strongly alters tryptophan metabolism resulting in increased secretion of the AHR ligand kynurenine. Silencing of EWSR1::ETS reduced killing of EwS cells by natural killer (NK) cells, while AHR silencing increases NK cell-mediated killing. From a cell-intrinsic perspective, AHR knockdown inhibits proliferation, clonogenic, and spheroidal growth of EwS cells in vitro, which can be recapitulated by pharmacological AHR inhibition. Furthermore, AHR knockdown decreases tumor growth and metastasis in vivo. Collectively, our results illustrate how oncogene-mediated metabolic reprogramming of amino acid metabolism can translate into more aggressive disease phenotypes in cancer.
Open AccessDynamic oncogene activity metabolically reprograms the tryptophan– kynurenine–AHR axis driving immune evasion and tumor progression in Ewing sarcoma
How activational changes of driver oncogenes can promote metabolic reprogramming and cancer progression is largely uncharted territory. To address this issue, we employed Ewing sarcoma (EwS) as a model as it is driven by a single driver oncogene, namely chimeric EWSR1::ETS fusion transcription factors, whose fluctuating expression levels promote diverse transcriptional programs. While EWSR1::ETS-high cells display a rather sessile but proliferative phenotype and EWSR1::ETS-low cells are more invasive, the mechanisms underlying these different phenotypes remain poorly characterized. Here, using an integrative functional genomics approach, we show that low EWSR1::ETS fusion activity in patient tumors associates with poor outcome and increased signaling of the aryl hydrocarbon receptor (AHR). AHR signaling enrichment correlates with increased tumor infiltration by immunosuppressive cells and worse overall patient survival. Knockdown of EWSR1::ETS in EwS spheroid models cultured in human plasma-like media strongly alters tryptophan metabolism resulting in increased secretion of the AHR ligand kynurenine. Silencing of EWSR1::ETS reduced killing of EwS cells by natural killer (NK) cells, while AHR silencing increases NK cell-mediated killing. From a cell-intrinsic perspective, AHR knockdown inhibits proliferation, clonogenic, and spheroidal growth of EwS cells in vitro, which can be recapitulated by pharmacological AHR inhibition. Furthermore, AHR knockdown decreases tumor growth and metastasis in vivo. Collectively, our results illustrate how oncogene-mediated metabolic reprogramming of amino acid metabolism can translate into more aggressive disease phenotypes in cancer.
- Open Access
Physiologically refined cell culture conditions uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids
SUMMARY: Ewing sarcoma (EwS) cell line culture largely relies on standard techniques, which do not recapitulate physiological conditions. Here, we report on a physiologically improved, feasible, and cost-efficient EwS cell culture technique employing an advanced medium composition, reduced fetal calf serum, and spheroidal growth. Functional in vitro assays and transcriptome profiling demonstrated that these refined conditions better recapitulate proliferation rates of patient tumors as well as hypoxic conditions relevant for EwS pathophysiology. Moreover, transcriptional signatures associated with the oncogenic activity of the EwS-specific FET::ETS fusion transcription factors in the refined culture conditions were shifted from proliferative towards metabolic gene signatures. The herein presented optimized physiological EwS cell culture technique provides a broadly applicable approach for enhanced in vitro modeling relevant to advancing EwS research and the validity of experimental results. MOTIVATION: Cell culture remains the main platform to model EwS for research purposes. Yet, concerns exist about the limitations of standard in vitro techniques to adequately reflect physiological conditions. In this study, we refined EwS cell culture methods to increase modeling capacity while ensuring a practical and cost-effective handling, thereby broadening their applicability within the scientific community.
Open AccessPhysiologically refined cell culture conditions uncover oncogene-dependent metabolic signatures in Ewing sarcoma spheroids
SUMMARY: Ewing sarcoma (EwS) cell line culture largely relies on standard techniques, which do not recapitulate physiological conditions. Here, we report on a physiologically improved, feasible, and cost-efficient EwS cell culture technique employing an advanced medium composition, reduced fetal calf serum, and spheroidal growth. Functional in vitro assays and transcriptome profiling demonstrated that these refined conditions better recapitulate proliferation rates of patient tumors as well as hypoxic conditions relevant for EwS pathophysiology. Moreover, transcriptional signatures associated with the oncogenic activity of the EwS-specific FET::ETS fusion transcription factors in the refined culture conditions were shifted from proliferative towards metabolic gene signatures. The herein presented optimized physiological EwS cell culture technique provides a broadly applicable approach for enhanced in vitro modeling relevant to advancing EwS research and the validity of experimental results. MOTIVATION: Cell culture remains the main platform to model EwS for research purposes. Yet, concerns exist about the limitations of standard in vitro techniques to adequately reflect physiological conditions. In this study, we refined EwS cell culture methods to increase modeling capacity while ensuring a practical and cost-effective handling, thereby broadening their applicability within the scientific community.